YOLFTbeta
24

Il Dong Pharmaceutical Co Ltd

249420 · KO · Healthcare / Drug Manufacturers - Specialty & Generic

12,570.00KRW-110.00 (-0.87%)

Price History

Full chart

Market Stats

Previous Close12,680.00
Open12,610.00
Day Range12,520.00 – 13,610.00
52-Week Range11,250.00 – 44,752.15
Volume64.93K
Market Cap457.18B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield1.37%
Beta0.89
50-Day Avg14,551.20
200-Day Avg25,179.30

About

Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-cancer, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central nervous system, dental, endocrine and metabolic system, gastrointestinal system, respiratory system, and urogenital system applications. It also provides raw material drugs; health foods and foods; beverages; cosmetics; medical devices for scar treatment; and other drugs for treating thick wounds, osteoarthritis, periarthritis of shoulder, and artificial tears, as well as feminine cleanser products. The company was founded in 1941 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOYun Paul Woongsup
  • Employees1.05K
  • Headquarters2, Baumoe-ro 27-gil, Seoul, South Korea, 137-130, Korea
  • Websitehttps://www.ildong.com

Leadership

  • Yun Paul WoongsupCEO & Chairman

Financials

Income Statement

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue201.34B460.65B503.91B517.47B561.85B560.13B637.71B600.76B614.94B566.93B
Growth (%)-+128.79%+9.39%+2.69%+8.58%-0.30%+13.85%-5.80%+2.36%-7.81%
Cost of Revenue104.05B234.42B248.75B285.11B323.43B340.69B401.37B386.91B381.48B347.18B
Gross Profit97.30B226.23B255.16B232.36B238.41B219.44B236.34B213.85B233.46B219.75B
Gross Margin48.32%49.11%50.64%44.90%42.43%39.18%37.06%35.60%37.96%38.76%
Operating Expense82.50B200.87B226.81B233.73B231.78B273.82B309.68B267.26B220.32B200.25B
Operating Income14.79B25.36B28.34B-1.37B6.63B-54.38B-73.33B-53.42B13.13B19.50B
Operating Margin7.35%5.51%5.62%-0.27%1.18%-9.71%-11.50%-8.89%2.14%3.44%
EBITDA-42.62B43.63B10.51B22.61B-101.34B-80.49B-51.23B31.18B66.50B
EBITDA Margin-9.25%8.66%2.03%4.02%-18.09%-12.62%-8.53%5.07%11.73%
Net Income12.58B19.84B12.72B-13.44B-13.02B-99.71B-141.58B-78.93B-4.58B27.66B
Net Income Margin6.25%4.31%2.52%-2.60%-2.32%-17.80%-22.20%-13.14%-0.74%4.88%
R&D12.51B33.36B46.46B48.50B60.18B96.52B109.90B95.02B46.27B35.60B
R&D as % of Total Revenue6.21%7.24%9.22%9.37%10.71%17.23%17.23%15.82%7.52%6.28%
Interest Expense003.59B5.23B4.67B10.56B9.79B14.72B15.94B12.17B
Interest Expense % of Total Revenue0.00%0.00%0.71%1.01%0.83%1.88%1.53%2.45%2.59%2.15%

Balance Sheet

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets550.35B564.63B564.67B612.72B605.28B708.97B655.81B611.26B589.04B573.03B
Total Liabilities281.94B279.55B287.84B359.83B350.73B548.39B457.59B437.00B429.99B333.52B
Total Equity268.41B285.07B276.82B252.89B254.55B152.91B191.24B169.54B160.76B246.42B
Cash19.90B39.94B75.94B89.96B85.56B135.59B52.15B53.26B72.27B64.85B
Net Debt-90.46B54.46B40.44B44.84B55.22B105.60B139.24B110.03B53.78B

Cash Flow

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow45.98B73.72B66.65B41.37B19.37B-11.37B-53.54B-36.62B28.29B18.95B
Investing Cash Flow-33.08B-47.88B-22.60B-14.03B-18.40B-43.37B-26.44B---
Financing Cash Flow-295.96M-5.41B-7.91B-13.48B-4.58B104.32B-3.29B---
Capital Expenditure14.22B16.73B15.09B12.06B14.35B14.63B11.87B18.19B14.05B17.33B
Free Cash Flow-28.88B45.86B22.01B160.22M-31.16B-73.15B-54.80B14.24B1.62B
Dividends Paid5.35B5.35B7.85B8.63B120.00M120.00M120.00M160.00M76.80M60.16M
FCF to OCF-39.17%68.81%53.21%0.83%274.12%136.62%149.67%50.33%8.56%
Dividend Paid to FCF-18.54%17.12%39.22%74.90%-0.39%-0.16%-0.29%0.54%3.71%

Earnings

Report DateApr 23, 2017Jul 26, 2017Nov 14, 2017Feb 20, 2018Apr 24, 2018Jul 24, 2018Nov 14, 2018Feb 15, 2019Apr 30, 2019Jul 29, 2019Oct 30, 2019Feb 14, 2020May 7, 2020Aug 12, 2020Nov 16, 2020Feb 19, 2021May 17, 2021Jul 29, 2021Nov 3, 2021Feb 17, 2022Mar 31, 2022Jul 27, 2022Oct 24, 2022Feb 9, 2023May 15, 2023Aug 9, 2023Nov 6, 2023Feb 8, 2024May 9, 2024Jul 31, 2024Oct 30, 2024Feb 3, 2025May 12, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate--340.26271.43226.76-------68.91129.25---33.13-84.96---1065.00-1065.00-1149.00---------------
EPS Actual107.68223.07349.78196.95259.41259.41131.75-122.86242.20259.05-202.86-265.71-52.00262.0038.00-795.58-542.00128.00-354.00-3940.92-4855.00-4855.00-626.00-2013.80-388.82-892.53-1710.9250.69-29.83-115.96-286.35268.3136.79-107.59745.84223.57262.32180.83
Surprise--2.80%-27.44%14.40%--------175.46%102.71%---1535.98%250.66%---355.87%-355.87%45.52%---------------
TimingPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-market-----

Key Statistics & Ratios

Market Cap457.18B
Enterprise Value506.86B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.79
Price / Book1.69
Revenue (TTM)582.33B
Gross Profit (TTM)230.53B
EBITDA47.61B
Profit Margin7.49%
Operating Margin2.45%
Return on Equity18.50%
Return on Assets2.79%
Shares Outstanding31.51M
Shares Float20.60M
Beta0.89
Dividend Yield1.37%
Dividend Rate200.00
Payout Ratio14.16%

Dividends

20261×
200.00Mar 30, 2026
20191×
95.24Dec 27, 2019
20181×
380.95Dec 27, 2018
20171×
362.81Dec 27, 2017
20161×
224.88Dec 28, 2016

Stock Splits

  • Mar 5, 20201.05:1
  • Dec 27, 20181.05:1
  • Dec 27, 20171.1:1
  • Dec 28, 20161.1:1